High-Dose Chemotherapy of Cyclophosphamide, Thiotepa, and Carboplatin (CTCb) Followed by Autologous Stem-Cell Transplantation for Metastatic Breast Cancer Patients: A 6-Year Follow-Up Result / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
;
: 24-30, 2005.
Artículo
en Inglés
| WPRIM
| ID: wpr-18126
ABSTRACT
PURPOSE:
The benefit of high-dose chemotherapy (HDC) for metastatic breast cancer (MBC) is controversial. We evaluated the efficacy and safety of HDC with cyclophosphamide, thiotepa, and carboplatin (CTCb) followed by autologous stem-cell transplantation (ASCT) for MBC patients. MATERIALS ANDMETHODS:
From September 1994 to December 1999, 23 MBC patients were enrolled. All the patients received 2 to 10 cycles of induction chemotherapy. Before transplantation, 12 patients were in complete response (CR), nine were in partial response (PR), and two had progressive disease (PD). The HDC regimen consisted of cyclophosphamide 1, 500 mg/m2/day, thiotepa 125 mg/m2/day and carboplatin 200 mg/m2/day intravenously for 4 consecutive daysRESULTS:
After ASCT, 13 patients (56%) had a CR, five (22%) had a PR, three (13%) had no change, while two (9%) showed a PD. Seventeen patients relapsed or progressed during the median follow-up of 78 months. The median progression-free survival (PFS) time was 11 months and the median overall survival (OS) time was 23 months. The 5-year PFS and OS rates were 22% and 25%, respectively. On the multivariate analyses, less than 4 involved lymph nodes was predictive of a better PFS and OS.CONCLUSION:
HDC with CTCb for MBC has acceptable toxicity; however, this treatment does not show a survival benefit.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Mama
/
Neoplasias de la Mama
/
Análisis Multivariante
/
Estudios de Seguimiento
/
Carboplatino
/
Tiotepa
/
Supervivencia sin Enfermedad
/
Ciclofosfamida
/
Quimioterapia
/
Quimioterapia de Inducción
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
/
Factores de riesgo
Límite:
Humanos
Idioma:
Inglés
Revista:
Cancer Research and Treatment
Año:
2005
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS